Income Taxes (Narrative) (Details) (USD $)
Share data in Millions, unless otherwise specified |
0 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 20, 2010
|
Jul. 29, 2010
|
Mar. 26, 2011
|
Dec. 31, 2011
|
Dec. 25, 2010
|
Dec. 26, 2009
|
Dec. 31, 2011
Investments in Foreign Subsidiaries that are Essentially Permanent in Duration [Member]
|
Dec. 25, 2010
Income Tax Expense [Member]
|
Dec. 25, 2010
Cumulated Translation Adjustment [Member]
|
Aug. 26, 2010
Accelerated stock repurchase program entered into on August 26, 2010
|
Jun. 12, 2006
2.25% Senior convertible debentures
|
Jun. 20, 2006
2.25% Senior convertible debentures
|
Dec. 31, 2011
2.25% Senior convertible debentures
|
Dec. 25, 2010
2.25% Senior convertible debentures
|
|
Income Tax Contingency [Line Items] | ||||||||||||||
Pool of excess tax benefits | $ 10,580,000 | $ 12,614,000 | ||||||||||||
Tax detriment recorded to additional pain-in-capital related to exercise of stock options and vesting of restricted shares | 802,000 | |||||||||||||
Increase in valuation allowance | 137,000 | |||||||||||||
Valuation allowance | 12,178,000 | 12,041,000 | ||||||||||||
Income tax benefit associated with a tax loss incurred with the disposition of Phase I clinical business | 11,111,000 | |||||||||||||
Authorized amount of stock repurchase | 750,000,000 | 500,000,000 | 300,000,000 | |||||||||||
Undistributed earnings of foreign subsidiaries, previously reinvested | 229,792,000 | |||||||||||||
Basis in foreign subsidiaries to be repatriated | 63,640,000 | |||||||||||||
Cost of repatriation of foreign earnings | 10,334,000 | 15,264,000 | (4,930,000) | |||||||||||
Foreign earnings repatriated during the period | 293,432,000 | |||||||||||||
Termination fee | 0 | 30,000,000 | 0 | |||||||||||
Earnings of non-U.S. subsidiaries considered indefinitely reinvested | 106,504,000 | |||||||||||||
Provision for U.S. income taxes | 0 | |||||||||||||
Aggregate principal amount | 300,000,000 | 350,000,000 | ||||||||||||
Additional principal amount issued | 50,000,000 | |||||||||||||
Net proceeds from issuance of debt | 294,000,000 | 49,000,000 | ||||||||||||
Interest rate on debt (as a percent) | 2.25% | 2.25% | 2.25% | 2.25% | ||||||||||
Unamortized debt discount | $ 88,492,000 | $ 21,533,000 | $ 35,583,000 | |||||||||||
Warrants issued (in shares) | 7.2 | |||||||||||||
Original issue discount (OID) deduction period (in years) | 7 years |